Abstract:Metformin exerts its anticancer effect through two mechanisms, directly affecting the tumor and indirectly reducing systemic insulin levels. The anticancer effects of aspirin occur by inhibiting Cyclooxygenase (COX)-2. COX-2 is absent in many cell types under normal conditions and increases under pathological conditions such as cancer. This study aims to investigate the effect of metformin and aspirin and their combination of them on A549 and PC3 cell lines. Metformin and aspirin were investigated separately and in combination on two cancer cell lines, A549 and PC3. The examined groups include the negative control of untreated cells and the positive control of cisplatin and drugs at concentrations of 15, 10, and 20 μg/ mL to investigate the mechanism of oxidative stress factors (reactive oxygen species, lipid peroxidation, Glutathione (GSH)) and apoptosis (lactate dehydrogenase). The results showed that aspirin, metformin, and their combination could affect cancer cell growth by damaging mitochondria, releasing reactive oxygen species, and activating the oxidative stress pathway. Also, these two drugs show the activation of the apoptotic pathway in cancer cells by increasing the lactate dehydrogenase factor and releasing it from the cells. By disrupting the balance of oxidants and antioxidants in the cell, metformin and aspirin cause an increase in the level of reactive oxygen species and a decrease in the level of glutathione reserves, followed by an increase in the level of lipid peroxidation and a decrease in cell viability. Unlike common chemotherapy drugs, these drugs have no known severe side effects; Therefore, in the not-so-distant future, these drugs can also be used as anticancer drugs. Highlights: Metformin and aspirin, commonly used drugs for diabetes and inflammation, inhibit the growth of cancer cell lines, A549 and PC3.Metformin and aspirin, either separately or in combination, can potentially impede cancer cell growth by disrupting mitochondrial function, inducing the release of reactive oxygen species (ROS), and activating oxidative stress pathways.Furthermore, these drugs can trigger apoptosis, a programmed cell death mechanism, in cancer cells by increasing lactate dehydrogenase (LDH) levels and facilitating its release from the cells.

Impact of Combination Therapy with Chemical Drugs and Megavoltage X-ray Exposure on Breast Cancer Stem Cells' Viability and Proliferation of MCF-7 and MDA-MB-231 Cell Lines

Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines

Synergistic anticancer effects of doxorubicin and metformin combination therapy: A systematic review

Metformin Synergistically Suppress Tumor Growth with Doxorubicin and Reverse Drug Resistance by Inhibiting the Expression and Function of P-glycoprotein in MCF7/ADR Cells and Xenograft Models

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Metformin Enhances Radiation Response of ECa109 Cells Through Activation of ATM and AMPK

Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells

The effects of metformin and PCL-sorafenib nanoparticle co-treatment on MCF-7 cell culture model of breast cancer

Electroporation-mediated Metformin for effective anticancer treatment of triple-negative breast cancer cells

Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action

Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization

Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification

Metformin-loaded chitosan nanoparticles augment silver nanoparticle-induced radiosensitization in breast cancer cells during radiation therapy

Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition

Abstract B029: Combinations of metformin and BH3-mimetic drugs synergistically induce immunogenic cell death in breast cancer cells

Co-delivery of metformin enhances the anti-multidrug resistant tumor effect of doxorubicin by improving hypoxic tumor microenvironment.

Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production

Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells

In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network